COHANCE Share Price Performance
₹296.10
-839.05 (-73.92%)
42.2% undervalued intrinsic discount
₹512.67
Fair Value
Price ₹296.10
AnalystConsensusTarget ₹512.67
AnalystHighTarget ₹1,111.73
AnalystLowTarget ₹640.00
Fair Value₹512.67
Share Pricen/a
Cohance Lifesciences Limited Stock Price
- 3 Narratives written by author
- 0 Comments on narratives written by author
- 14 Fair Values set on narratives written by author
COHANCE Community Narratives
AN
Fair Value ₹512.67 42.2% undervalued intrinsic discount
COHANCE: New Facility Expansions Will Drive Future Opportunity And Margins
0users have liked this narrative
0users have commented on this narrative
7users have followed this narrative
AN
Fair Value ₹1.11k 73.4% undervalued intrinsic discount
ADCs And Oligonucleotides Will Reshape This CDMO’s Earnings Power Over Time
0users have liked this narrative
0users have commented on this narrative
0users have followed this narrative
AN
Fair Value ₹640 53.7% undervalued intrinsic discount
ADC Payload Scaling Risks And Regulatory Hurdles Will Shape Long-Term Margin Upside
0users have liked this narrative
0users have commented on this narrative
0users have followed this narrative
COHANCE: New Facility Expansions Will Drive Future Opportunity And Margins
Key Takeaways Strategic acquisitions and entry into high-growth segments enhance revenue and margins by tapping into high-value markets like oligonucleotides and ADCs. Diversification and expansion into specialty segments with differentiated technology and M&A bolster competitive advantage and drive predictable, accelerated growth. Strategic acquisition reliance and volatile demand may strain cash flow, impacting financial stability, margins, and long-term earnings if expected synergies aren't realized.Read more
143
users have viewed this narrative0users have liked this narrative
0users have commented on this narrative
7users have followed this narrative
AN
₹512.67
42.2% undervalued intrinsic discount
AnalystConsensusTarget's Fair Value
Revenue
56.24% p.a.
Profit Margin
16.71%
Future PE
40.54x
Price in 2029
₹729.07
ADCs And Oligonucleotides Will Reshape This CDMO’s Earnings Power Over Time
Catalysts About Cohance Lifesciences Cohance Lifesciences operates a diversified pharma CDMO, API and specialty chemicals platform serving global innovators and biotechs across complex small molecules and newer modalities. What are the underlying business or industry changes driving this perspective?Read more
17
users have viewed this narrative0users have liked this narrative
0users have commented on this narrative
0users have followed this narrative
AN
₹1.11k
73.4% undervalued intrinsic discount
AnalystHighTarget's Fair Value
Revenue
65.46% p.a.
Profit Margin
20.97%
Future PE
64.84x
Price in 2029
₹1.96k
ADC Payload Scaling Risks And Regulatory Hurdles Will Shape Long-Term Margin Upside
Catalysts About Cohance Lifesciences Cohance Lifesciences is a diversified pharma and specialty chemicals company providing CDMO, API and advanced intermediate solutions to global innovators across small molecules, ADCs and oligonucleotides. What are the underlying business or industry changes driving this perspective?Read more
4
users have viewed this narrative0users have liked this narrative
0users have commented on this narrative
0users have followed this narrative
AN
₹640
53.7% undervalued intrinsic discount
AnalystLowTarget's Fair Value
Revenue
52.68% p.a.
Profit Margin
19.45%
Future PE
51.21x
Price in 2028
₹917.53
Trending Discussion
Recently Updated Narratives
AN
COHANCE: FDA Warning Letter Remediation Will Support Confidence In Future Prospects
Fair Value: ₹512.67 42.2% undervalued intrinsic discount
7 followersusers have followed this narrative
0 commentsusers have commented on this narrative
0 likesusers have liked this narrative
AN
ADCs And Oligonucleotides Will Reshape This CDMO’s Earnings Power Over Time
Fair Value: ₹1.11k 73.4% undervalued intrinsic discount
0 followersusers have followed this narrative
0 commentsusers have commented on this narrative
0 likesusers have liked this narrative
AN
ADC Payload Scaling Risks And Regulatory Hurdles Will Shape Long-Term Margin Upside
Fair Value: ₹640 53.7% undervalued intrinsic discount
0 followersusers have followed this narrative
0 commentsusers have commented on this narrative
0 likesusers have liked this narrative
Snowflake Analysis
Cohance Lifesciences Limited Key Details
About COHANCE
- Founded
- 1989
- Employees
- 1212
- CEO
- WebsiteView website
Cohance Lifesciences Limited engages in the contract research, development, and manufacturing of new chemical entity (NCE) based intermediates, active pharmaceutical ingredients (API), specialty chemicals, and formulated drugs in India, the United States, Europe, and internationally. The company offers small molecule APIs, advanced intermediates, and starting materials; antibody drug conjugates; high-purity oligonucleotide building blocks comprising phosphoramidites, nucleosides, pseudouridine, NTPs, CAP reagents, GalNAc conjugates, and fluorescent dyes; pellets and finished dosage forms; and specialty chemicals, including agrochemicals. It serves pharmaceutical, biotechnology, and chemical companies. The company was formerly known as Suven Pharmaceuticals Limited and changed its name to Cohance Lifesciences Limited in May 2025. The company was founded in 1989 and is headquartered in Hyderabad, India. Cohance Lifesciences Limited is a subsidiary of Berhyanda Limited.
